Brokerages Expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to Post $0.10 EPS

Equities analysts expect that Meridian Bioscience, Inc. (NASDAQ:VIVO) will report earnings per share of $0.10 for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Meridian Bioscience’s earnings, with the lowest EPS estimate coming in at $0.07 and the highest estimate coming in at $0.12. Meridian Bioscience posted earnings of $0.18 per share during the same quarter last year, which would indicate a negative year over year growth rate of 44.4%. The business is expected to announce its next quarterly earnings results on Tuesday, July 30th.

According to Zacks, analysts expect that Meridian Bioscience will report full year earnings of $0.56 per share for the current fiscal year, with EPS estimates ranging from $0.52 to $0.62. For the next year, analysts forecast that the business will post earnings of $0.54 per share, with EPS estimates ranging from $0.49 to $0.62. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.04. The firm had revenue of $50.25 million for the quarter, compared to the consensus estimate of $50.03 million. Meridian Bioscience had a return on equity of 18.58% and a net margin of 13.29%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period last year, the business posted $0.21 EPS.

A number of equities analysts recently commented on the company. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Saturday, June 15th. Canaccord Genuity reaffirmed a “buy” rating and issued a $1.80 target price on shares of Meridian Bioscience in a report on Wednesday, June 5th. BidaskClub raised Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, May 29th. Finally, Piper Jaffray Companies raised Meridian Bioscience from an “underweight” rating to a “neutral” rating and decreased their target price for the stock from $15.00 to $11.00 in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $11.45.

VIVO stock opened at $11.69 on Friday. The firm has a market capitalization of $499.25 million, a PE ratio of 15.80 and a beta of 0.30. Meridian Bioscience has a 1 year low of $10.77 and a 1 year high of $19.84. The company has a current ratio of 6.01, a quick ratio of 4.31 and a debt-to-equity ratio of 0.23.

In related news, CEO John P. Kenny bought 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The shares were bought at an average cost of $11.49 per share, with a total value of $229,800.00. Following the acquisition, the chief executive officer now owns 83,000 shares in the company, valued at $953,670. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James M. Anderson purchased 5,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were acquired at an average cost of $11.37 per share, for a total transaction of $56,850.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 32,000 shares of company stock worth $366,170. 2.00% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Meeder Asset Management Inc. raised its holdings in Meridian Bioscience by 196.7% during the first quarter. Meeder Asset Management Inc. now owns 1,552 shares of the company’s stock valued at $27,000 after acquiring an additional 1,029 shares during the period. Quadrant Capital Group LLC raised its holdings in Meridian Bioscience by 441.6% during the first quarter. Quadrant Capital Group LLC now owns 1,874 shares of the company’s stock valued at $31,000 after acquiring an additional 1,528 shares during the period. Quantamental Technologies LLC bought a new stake in Meridian Bioscience during the first quarter valued at about $56,000. LS Investment Advisors LLC raised its holdings in Meridian Bioscience by 158.3% during the fourth quarter. LS Investment Advisors LLC now owns 3,719 shares of the company’s stock valued at $65,000 after acquiring an additional 2,279 shares during the period. Finally, BNP Paribas Arbitrage SA raised its holdings in Meridian Bioscience by 298.7% during the first quarter. BNP Paribas Arbitrage SA now owns 9,688 shares of the company’s stock valued at $171,000 after acquiring an additional 7,258 shares during the period. 90.35% of the stock is currently owned by institutional investors and hedge funds.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

See Also: Back-End Load

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.